ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX

A California jury ruled in favor of ImprimisRx in a trademark infringement lawsuit against OSRX and Ocular Science, awarding $34.9 million in damages. ImprimisRx’s CEO, Mark L. Baum, expressed satisfaction with the verdict, emphasizing the defense of their intellectual property. However, OSRX has stated that the legal battle is not over, citing unresolved issues such as laches, unclean hands, and fraud on the USPTO. The trial judge is set to decide on these matters in December. ImprimisRx had originally also filed false advertising and copyright claims, which were either abandoned or ruled in favor of OSRX, respectively.

Source link